Secretory Leukocyte Peptidase Inhibitor and Lung Cancer

Overview

Journal Cancer Sci

Specialty Oncology

Date 2008 Apr 3

PMID 18380788

Citations 27

Authors

Toshihiro Nukiwa

Takuji Suzuki

Tatsuro Fukuhara

Toshiaki Kikuchi

Affiliations

Soon will be listed here.

Abstract

Secretory leukocyte peptidase inhibitor (SLPI) belongs to the whey acidic protein four-disulfide core family of proteins, and has antimicrobial and antiprotease functions. SLPI is produced by the epithelial cells lining the respiratory, digestive, and reproductive tracts. Gene-targeting experiments in mice indicated that one function of SLPI is to protect proepithelin from elastase cleavage in wound healing. In addition to its antiprotease function, SLPI has an anti-inflammatory function through the modulation of nuclear factor-kappaB acting intracellularly, especially in macrophages. SLPI is also produced in cancer tissues, but its role in cancer is not well understood. SLPI genes are often upregulated under tumorigenic conditions. We found a negligible number of tumors in the lungs of SLPI knockout mice 20 or 40 weeks after administration of urethane, an interesting experimental model for investigating the function of SLPI in cancer. This review discusses the normal function of SLPI and its possible roles in cancer tissues.

Citing Articles

Lung antimicrobial proteins and peptides: from host defense to therapeutic strategies.

Di Y, Kuhn J, Mangoni M Physiol Rev. 2024; 104(4):1643-1677.

PMID: 39052018 PMC: 11495187. DOI: 10.1152/physrev.00039.2023.

The secretory leukocyte protease inhibitor (SLPI) in pathophysiology of non-communicable diseases: Evidence from experimental studies to clinical applications.

Mongkolpathumrat P, Pikwong F, Phutiyothin C, Srisopar O, Chouyratchakarn W, Unnajak S Heliyon. 2024; 10(2):e24550.

PMID: 38312697 PMC: 10835312. DOI: 10.1016/j.heliyon.2024.e24550.

Dietary iron modulates gut microbiota and induces SLPI secretion to promote colorectal tumorigenesis.

Liu C, Gong J, Zhang Q, Chen G, Yin S, Luo Z Gut Microbes. 2023; 15(1):2221978.

PMID: 37312410 PMC: 10269393. DOI: 10.1080/19490976.2023.2221978.

Up-regulation of secretory leukocyte protease inhibitor in human samples might have a potential role of predicting prostate cancer recurrence and progression after surgery and hormonal therapy.

Miyazaki Y, Goto T, Li X, Nakayama K, Okasho K, Takeda M Cancer Med. 2023; 12(3):3328-3342.

PMID: 36812122 PMC: 9939162. DOI: 10.1002/cam4.5134.

Inhibition of secretory leukocyte protease inhibitor (SLPI) promotes the PUMA-mediated apoptosis and chemosensitivity to cisplatin in colorectal cancer cells.

Wei Z, Liu G, Jia R, Zhang W, Li L, Zhang Y Discov Oncol. 2023; 14(1):1.

PMID: 36595102 PMC: 9810770. DOI: 10.1007/s12672-022-00535-9.

References

Couto M, Harwig S, Lehrer R . Selective inhibition of microbial serine proteases by eNAP-2, an antimicrobial peptide from equine neutrophils. Infect Immun. 1993; 61(7):2991-4. PMC: 280950. DOI: 10.1128/iai.61.7.2991-2994.1993. View

Viatour P, Dejardin E, Warnier M, Lair F, Claudio E, Bureau F . GSK3-mediated BCL-3 phosphorylation modulates its degradation and its oncogenicity. Mol Cell. 2004; 16(1):35-45. DOI: 10.1016/j.molcel.2004.09.004. View

Kluger H, Lev D, Kluger Y, McCarthy M, Kiriakova G, Camp R . Using a xenograft model of human breast cancer metastasis to find genes associated with clinically aggressive disease. Cancer Res. 2005; 65(13):5578-87. DOI: 10.1158/0008-5472.CAN-05-0108. View

Israeli O, Goldring-Aviram A, Rienstein S, Ben-Baruch G, Korach J, Goldman B . In silico chromosomal clustering of genes displaying altered expression patterns in ovarian cancer. Cancer Genet Cytogenet. 2005; 160(1):35-42. DOI: 10.1016/j.cancergencyto.2004.11.011. View

Hiemstra P, Maassen R, Stolk J, Heinzel-Wieland R, Steffens G, Dijkman J . Antibacterial activity of antileukoprotease. Infect Immun. 1996; 64(11):4520-4. PMC: 174407. DOI: 10.1128/iai.64.11.4520-4524.1996. View

Devoogdt N, Hassanzadeh Ghassabeh G, Zhang J, Brys L, De Baetselier P, Revets H . Secretory leukocyte protease inhibitor promotes the tumorigenic and metastatic potential of cancer cells. Proc Natl Acad Sci U S A. 2003; 100(10):5778-82. PMC: 156277. DOI: 10.1073/pnas.1037154100. View

Wang N, Thuraisingam T, Fallavollita L, Ding A, Radzioch D, Brodt P . The secretory leukocyte protease inhibitor is a type 1 insulin-like growth factor receptor-regulated protein that protects against liver metastasis by attenuating the host proinflammatory response. Cancer Res. 2006; 66(6):3062-70. DOI: 10.1158/0008-5472.CAN-05-2638. View

Zhang Y, Dewitt D, McNeely T, Wahl S, Wahl L . Secretory leukocyte protease inhibitor suppresses the production of monocyte prostaglandin H synthase-2, prostaglandin E2, and matrix metalloproteinases. J Clin Invest. 1997; 99(5):894-900. PMC: 507897. DOI: 10.1172/JCI119254. View

Rosen E, Knesel J, Goldberg I, Jin L, Bhargava M, Joseph A . Scatter factor modulates the metastatic phenotype of the EMT6 mouse mammary tumor. Int J Cancer. 1994; 57(5):706-14. DOI: 10.1002/ijc.2910570517. View

10.

Zhang D, Simmen R, Michel F, Zhao G, Vale-Cruz D, Simmen F . Secretory leukocyte protease inhibitor mediates proliferation of human endometrial epithelial cells by positive and negative regulation of growth-associated genes. J Biol Chem. 2002; 277(33):29999-30009. DOI: 10.1074/jbc.M203503200. View

11.

Schlingemann J, Hess J, Wrobel G, Breitenbach U, Gebhardt C, Steinlein P . Profile of gene expression induced by the tumour promotor TPA in murine epithelial cells. Int J Cancer. 2003; 104(6):699-708. DOI: 10.1002/ijc.11008. View

12.

Ma G, Greenwell-Wild T, Lei K, Jin W, Swisher J, Hardegen N . Secretory leukocyte protease inhibitor binds to annexin II, a cofactor for macrophage HIV-1 infection. J Exp Med. 2004; 200(10):1337-46. PMC: 2211913. DOI: 10.1084/jem.20041115. View

13.

Kikuchi T, Abe T, Satoh K, Narumi K, Sakai T, Abe S . Cis-acting region associated with lung cell-specific expression of the secretory leukoprotease inhibitor gene. Am J Respir Cell Mol Biol. 1997; 17(3):361-7. DOI: 10.1165/ajrcmb.17.3.2212. View

14.

Doumas S, Kolokotronis A, Stefanopoulos P . Anti-inflammatory and antimicrobial roles of secretory leukocyte protease inhibitor. Infect Immun. 2005; 73(3):1271-4. PMC: 1064911. DOI: 10.1128/IAI.73.3.1271-1274.2005. View

15.

Kuba K, Matsumoto K, Date K, Shimura H, Tanaka M, Nakamura T . HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice. Cancer Res. 2000; 60(23):6737-43. View

16.

Sano C, Shimizu T, Sato K, Kawauchi H, Tomioka H . Effects of secretory leucocyte protease inhibitor on the production of the anti-inflammatory cytokines, IL-10 and transforming growth factor-beta (TGF-beta), by lipopolysaccharide-stimulated macrophages. Clin Exp Immunol. 2000; 121(1):77-85. PMC: 1905674. DOI: 10.1046/j.1365-2249.2000.01269.x. View

17.

Bild A, Yao G, Chang J, Wang Q, Potti A, Chasse D . Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature. 2005; 439(7074):353-7. DOI: 10.1038/nature04296. View

18.

Xu W, He B, Chiu A, Chadburn A, Shan M, Buldys M . Epithelial cells trigger frontline immunoglobulin class switching through a pathway regulated by the inhibitor SLPI. Nat Immunol. 2007; 8(3):294-303. DOI: 10.1038/ni1434. View

19.

Devoogdt N, Revets H, Kindt A, Liu Y, De Baetselier P, Hassanzadeh Ghassabeh G . The tumor-promoting effect of TNF-alpha involves the induction of secretory leukocyte protease inhibitor. J Immunol. 2006; 177(11):8046-52. DOI: 10.4049/jimmunol.177.11.8046. View

20.

McElvaney N, Nakamura H, Birrer P, Hebert C, Wong W, Alphonso M . Modulation of airway inflammation in cystic fibrosis. In vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor. J Clin Invest. 1992; 90(4):1296-301. PMC: 443173. DOI: 10.1172/JCI115994. View